In tumor-bearing mouse models, targeting CXCR2-mediated TAN mobilization has been reported to increase the number of tumor-infiltrating lymphocytes and potentiate anti-programmed death 1 checkpoint blockade [57,58,59,60]. This evidence concerns the gene CXCR2 and neoplasm.